Pfizer South Africa

Our Purpose

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer healthcare products.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

We believe that to be truly healthy, it takes more than medication. This is why Pfizer South Africa is a healthcare company that’s dedicated to helping South Africans live healthier lives.

“When you have your health, you cando whatever is a priority to you.

When you don’t, you can’t.

What I love about being part ofPfizer is that it’s always on our mind.”

Jennifer PowerCOUNTRY MANAGER

3

These business units are underpinned by Enabling Functions that advance all of the company’s businesses, organisations and priorities (such as Legal, Regulatory, HR, Business Technology, Finance and Public Affairs).

Pfizer Innovative Health (PIH) is committed to discovering, developing, manufacturing and delivering innovative products and vaccines that change the outcome of chronic conditions and devastating diseases.

The PIH portfolio includes existing treatments and the development of new treatments in the following therapy areas:

• Inflammation & Immunology

• Metabolic Disease & Cardiovascular Risk

• Neuroscience & Pain

• Oncology

• Rare Diseases

• Vaccines

Pfizer Essential Health (PEH) combines the history of industry leadership,

comprehensive knowledge of global healthcare markets, and a vast portfolio of trusted,

quality medicines to benefit patients around the world at virtually every stage of life.

The PEH portfolio includes medicines that treat patients for a variety of acute and

chronic conditions across many therapeutic areas, including many critical medicines and

sterile injectables:

• Anti-Infectives & Sedation

• Women’s and Men’s Health

• Cardiovascular Disease

• Neuroscience

• Pain

Pfizer Consumer Health (PCH) develops, manufactures and markets leading non-

prescription medicines, low risk medical devices (for external use) and health products

(mainly supplements).

Our Business

Our commercialbusiness is dividedinto three Business

Units, each of which broadly work in

different areas of medicine.

These Business Units are:

Pfizer Innovative Health (PIH),

Pfizer Essential Health (PEH),

and

Pfizer Consumer Health (PCH).

We have a culture of ownership and excellence, and empower our colleagues to achieve beyond their expectations within an open and inclusive environment. We focus intensely on colleague development and a joint commitment to excellence. We are working to drive transformation and contribute to socio-economic advancement via a holistic empowerment strategy aligned to the B-BBEE Act and Codes of Good Practice.

Our Culture and Values

We own and live our values to deliver on

customer expectations, and together make Pfizer

a wonderful place at which to work.

Integrity

Innovation

Respect for People

Customer Focus

Collaboration

Leadership

Performance

Community

Quality

“I would like people to think about Pfizer not as a building or a logo or a corporation, but rather as a collective of individuals who

are passionate about what they come to work to do every single day –

which is to help bring therapies to people that significantly improve their lives.”

Jennifer PowerCOUNTRY MANAGER

the business. in the marketplace.

Let’s discuss behaviors. results. in one another.

O W N I T

OWN WIN NO JERKS IMPACT TRUST

Seize opportunities to think differently,

take risks, try something new.

Advocate and drive long-term,

aligned strategies that advance our

mission and shape the industry.

Confront corrosive, self-serving and mean-spirited

behaviors: it’s everyone’s responsibility.

Deliver on commitments with speed, decisiveness,

and integrity.

Invest in candid and constructive debate to ensure

each other’s success:

it’s time forstraight talk.

Pfizer Worldwide

5

Cardiovascular

Inflammation

Gastroenterology Haematology

Biosimilars

MetabolicDisease

Oncology

InfectiousDiseases

Oncology &Inflammation

Vaccines

Pfizer Worldwide

175 Markets

64 Manufacturing Sites

134 Logistics Centres

200+ Supply Partners

24 500+ SKUs

40+Technologies / Platforms

150years

300+ Employees

850+ Major Product Groups

Therapeutic / Disease Areas Being Studied 9

200+ New R&D Collaborations

20+ Clinical Trials75

Trial Centres

One of SA’s Top 5 American Employers

9 700+ Employees

100 Different Prescription Products

Share Product and Disease Knowledge with 4000+ Healthcare Professionals

Pfizer Southern Africa

Opens in Brooklyn, New York as a fine chemical business

World’s largest producer of penicillin

Production of citric acid puts Pfizer on

the map

Becomes a publically traded company

1849 19441880s 1942History and Milestones of Pfizer South Africa

Leadership Team

“The most amazing part of my job

is being part of a team that finds

a solution to a problem without

an obvious answer.

It’s to innovate, to be part of improving

healthcare for individuals, and this team here at Pfizer

does that every singleday.”

Jennifer PowerCOUNTRY MANAGER

Jennifer PowerCOUNTRY MANAGER

Doreen NelHUMAN RESOURCES

DIRECTOR

Matthew MoodleyLEGAL DIRECTOR

William ThemaneBUSINESS ANALYTICS

& INSIGHTS LEAD

Larne PearsonPRODUCT QUALITY

LEAD

Mahnqwa KhumaloFINANCE DIRECTOR

Dr. Tobeka BoltinaMEDICAL DIRECTOR

Rhulani NhlanikiPFIZER INNOVATIVE

HEALTH CLUSTER LEAD

Bridget BarnardLOGISTICS & SUPPLY

CHAIN MANAGER

Paul BrandSALES DIRECTOR

Marianne ZennonCOUNTRY

REGULATORY HEAD

Elaine CrossBUSINESS

OPERATIONS LEAD

Carl SmithBUSINESS

TECHNOLOGY LEAD

Karen HulettMARKETING DIRECTOR

Atetia VisagieGLOBAL COMMERCIAL OPERATIONS CLUSTER

LEAD

Johnny MolotoDIRECTOR PUBLIC

AFFAIRS POLICY ACCESS & COMMUNICATIONS

Sue CartwrightPFIZER CONSUMER

HEALTH COMMERCIAL LEAD

7

Enters SA market with distribution via

Petersen Ltd.

Branches into agricultural sector

Acquires Choats Co. and African Chemical

Corporation

Sets up own pharmaceutical

promotional activity in SA

World headquarters established in

New York

Johannesburg becomes regional HQ

for Southern Africa

1951 1950s 19621953 1961 1967

Researchand Development Research and Development is at the heart of fulfilling our purpose to help people live healthier lives. Innovation is also the key to sustaining our growth and profitability. As such, the quest for innovative solutions invigorates the Pfizer community globally, and we have more than 200 new R&D collaborations active worldwide.

We are advancing next-generation science to accelerate the development of breakthrough medicines and vaccines, and translate technologies into therapies that significantly improve patients’ lives.

The process is arduous and expensive: it takes an average of 12 years for a drug to reach the market. We therefore focus our resources in disease areas with the best chance of scientific and commercial success. Clinical studies find the answers necessary to develop innovative new therapies, and clinical trials make it possible for participating patients to receive state-of-the-art care from the leading experts in the field.

In South Africa alone, we run over 20 Clinical Trials at 75 Trial Centres annually.

“We’re contributing to the knowledge economy, we’re contributing to innovation, and we are contributing to the man in the street in making sure that the right vaccine gets to where it needs to get to so that he can focus on other aspects of life.”

Scientific CollaborationsBiovac Technology Transfer The Pfizer-Biovac Technology Transfer is a public-private initiative to locally manufacture a vaccine crucial for the prevention of pneumonia-related deaths, particularly in children up to the age of five. Launched in 2015, the project entails a skills and technology transfer from Pfizer to Biovac that will provide it with the capability to manufacture the vaccine by 2019.

Morena MakhoanaBIOVAC CEO

Pietermaritzburg manufacturing plant

commissioned

Further acquisitions and mergers grow

the company

Celebrates 150th anniversaryForbes Company of the Year

Achieves Top 10 status in the industry

1968 1970s 1999

Our supplier quality management systems help ensure high quality materials are procured for our products.

Our conveyance security standards enable our medicines to be transported safely and help prevent illicit dugs from entering the corporate supply chain.

We enact applicable local market legislation and regulations that strengthen our supply chain.

Our security programmes help protect our warehousing facilities and warehouses from criminals.

Our global packaging technology programme is designed to help prevent counterfeiting of our products.

Our global bar coding programme allows us to add authentication capability to our products.

Our established monitoring systems help us scrutinise the marketplace for the presence of counterfeit and unsafe product.

Supply Chain

Security

History and Milestones of Pfizer South Africa

9

Merges with Warner-LambertTop 5 pharma company in SA

MoU with DoH: establishes anti-fungal partnership programme to help treatment of HIV/AIDS

Acquires Pharmacia Corporation

Partners with Biovac Institute in a Technology Transfer

Initiative

Acquires Wyeth

2000 2002 20152009

An environment in which everyone in Pfizer understands and embraces their responsibility for protecting product quality and patient safety. Quality Culture is and has always been the “key” to enable us to provide safe and quality medicines.

A holistic, multi-faceted approach to ensure product quality and adherence to Good Manufacturing Practice (cGMP).

Organised according to integrated and interconnected quality processes (such as Governance & Internal Organisation, Product Quality Assurance & Operations, Contractor / Supplier Management and Oversight) to ensure high and consistent product quality.

Ensures high commitment to Quality and Regulations from our suppliers, so that consistent compliance for products, processes and facilities is maintained.

Our global adverse event reporting database helps identify potential issues quickly, and helps ensure product quality and safety.

Processes and procedures for timely and accurate safety monitoring of investigational and marketed products.

We strive to provide the framework for quality and Environmental Health & Safety (EHS) challenges / risks through the successful collaboration with our industry, senior leadership and regulators.

Strong Quality Culture:

Management Oversight:

Global Quality Systems:

Supplier Standards / Oversight:

Adverse Event Reporting:

Quality / Safety Monitoring:

Innovation:

Drive Pfizer’s transformation to contribute to the country’s socio-economic advancement

Pfizer understands the B-BBEE policy and regulatory environment in South Africa and seeks to promote and achieve the objectives of B-BBEE by driving transformation from within its South African business. In order to do so, Pfizer believes that it should implement a holistic B-BBEE strategy which–

• is capable of making a significant impact on the beneficiaries of such B-BBEE strategy; and

• takes into account the content of the B-BBEE Act, as well as the applicable B-BBEE codes of good practice.

QualityControl

At Pfizer we have a proud tradition of ensuring that the communities in which we live and work benefit from our investment and from our partnerships with key stakeholders to expand access to treatment and affordable healthcare. Pfizer’s corporate responsibility activities are focused on investing the full range of our resources - people, skills, expertise and funding - to broaden access to medicines and strengthen healthcare delivery for underserved people around the world. Several of Pfizer’s corporate public health partnerships have had a positive impact on healthcare in South Africa and we have both a local and global social responsibility focus.

Our business strategy is aligned to South Africa’s socio-economic transformation priorities and we use the B-BBEE scorecard as the objective measure to track the progress we are making against all the critical elements. In this regard, our contribution to the local economy is a journey rather than an event. Every year, we build on our previous successes as part of our long-term commitment to the country.

Our Value Add

to the South

African Economy

Unjani Clinics Unjani Clinics is an Enterprise Development initiative that empowers black woman Professional Nurses to own and operate their own primary healthcare clinics in their communities, creating permanent jobs and building sustainable businesses. Founded on an owner-operator model, the clinics serve the “bottom of the pyramid” and underserved markets, ensuring an affordable, quality primary healthcare service and the supply of quality medicines to the people of South Africa. The clinics are based in communities, ensuring that the service is delivered at the point of need. Pfizer sponsored a clinic in Hammanskraal and has provided funding for 28 Mindray DP10 Ultrasonic Diagnostic Imaging Systems, printers, trolleys, as well as as certified training for 28 clinics in the network.

11

Antifungal Partnership ProgrammeSince 2000, Pfizer has been in partnership with the Department of Health, donating treatments for two opportunistic fungal infections associated with HIV and AIDS (cryptococcal meningitis and esophageal candidiasis). Sixteen years into the programme, South Africa has 1 264 sites, accounting for almost 50% of all the sites globally. In 2016 alone, the value of the programme was R200 million.

The Nelson Mandela Children’s Hospital (NMCH) NMCH is fast realising the late Nelson Mandela’s dream of a hospital offering the children of Southern Africa state-of-the-art healthcare. Pfizer donated R3 million towards the hospital’s construction and the purchase of two Ultrasound Imaging Units to detect cardiothoracic defects in babies and children.

Public Health Enhancement FundPfizer is a member of the Public Health Enhancement Fund (PHEF), which is a social compact between 23 private healthcare companies and the Ministry of Health. The purpose of the PHEF is to contribute towards the production of medical doctors, researchers in HIV/AIDS and TB as well as capacity building for public hospital administrators. Pfizer participates in this programme by making annual financial contributions based on a percentage of our earnings. There is therefore a direct correlation between what we earn from any transaction and what we give back to society.

“When a global company such as

Pfizer gets involved in a grassroots

initiative such as Unjani, I think

it’s important to South Africa. It’s

not only about empowerment of women and

job creation, but creating access

to much needed healthcare

services and better lives for all.

Isn’t itwonderful that

you can go to work every single

day and know that you are

actually making a difference.”

Lynda ToussaintUNJANI CLINICS CEO

0860 Pfizer (734937)

www.pfizer.co.za

Physical Address85 Bute Lane Sandton 2146

Postal AddressPfizer Laboratories (Pty) Ltd.PO Box 783720 Sandton 2196

Working Togetherfor a Healthier World®

Pfizer South Africa